Medtronic MDT came up with a mixed performance for the third quarter of fiscal 2025, sparking investor concerns and a ...

The BrainSense Adaptive technology is an enhancement to Medtronic’s Percept DBS neurostimulators. The advancement personalizes therapy based on a patient’s brain activity in real-time. Therapy ...

The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...

The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available nationwide in the next few months.

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...

New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever ...

Medtronic said the Food and Drug Administration approved a brain stimulation system for people afflicted with Parkinson's disease.

Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no ...

Medtronic's FDA-approved BrainSense Adaptive DBS system revolutionizes Parkinson's therapy with real-time adjustments for ...

The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with ...